Hill H Z, Hill G J, Miller C L, Pfaller M, Weiss K, Galin M
Cancer Res. 1979 Mar;39(3):934-9.
The effects of 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC), 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU), and L-phenylalanine mustard (L-PAM) have been compared by using three i.p. transplanted mouse melanomas: the B16 melanoma in C57BL/6 mice; the Harding-Passey (HP) malanoma in BALB/c X DBA/2F1 (hereafter called CD2F1) mice; and the Cloudman S91 melanoma in DBA/2 mice. HP melanoma responds well to all three drugs. S91 responds only to L-PAM and MeCCNU. DTIC may accelerate death in mice bearing this tumor. B16 responds well to L-PAM and moderately well to MeCCNU and to multiple injections of DTIC. The best response to DTIC and MeCCNU is given by HP, while the best response to L-PAM is given by S91. Tumor cell-doubling times were found to be 1.5 days for B16, 2 DAYS FOR HP, and 3 days for S91. HP would seem to be the most responsive malanmoma with respect to the 3 agents studied. This may be due to an interaction between the chemotherapeutic agents and the host immune response, since the HP tumor arose in a noninbred mouse and is thus nonsyngeneic with the CD2F1 host. All three tumors appear to be interesting biological models for studying drug combinations and combined therapeutic modalities against melanoma.
通过腹腔注射接种三种小鼠黑色素瘤,比较了5-(3,3-二甲基-1-三氮烯基)咪唑-4-甲酰胺(DTIC)、1-(2-氯乙基)-3-(4-甲基环己基)-1-亚硝基脲(MeCCNU)和L-苯丙氨酸氮芥(L-PAM)的效果:C57BL/6小鼠的B16黑色素瘤;BALB/c×DBA/2F1(以下简称CD2F1)小鼠的哈丁-帕西(HP)黑色素瘤;以及DBA/2小鼠的克劳德曼S91黑色素瘤。HP黑色素瘤对这三种药物均反应良好。S91仅对L-PAM和MeCCNU有反应。DTIC可能会加速携带这种肿瘤的小鼠死亡。B16对L-PAM反应良好,对MeCCNU和多次注射DTIC反应中等。HP对DTIC和MeCCNU的反应最佳,而S91对L-PAM的反应最佳。发现B16的肿瘤细胞倍增时间为1.5天,HP为2天,S91为3天。就所研究的三种药物而言,HP似乎是反应最灵敏的黑色素瘤。这可能是由于化疗药物与宿主免疫反应之间的相互作用,因为HP肿瘤源自非近交系小鼠,因此与CD2F1宿主非同基因。所有这三种肿瘤似乎都是用于研究针对黑色素瘤的联合用药和联合治疗模式的有趣生物学模型。